Retinal Sensitivity in BRVO After Anti-VEGF Therapy

NCT02527733 · clinicaltrials.gov ↗

PHASE4

Phase

UNKNOWN

Status

50

Enrollment

OTHER

Sponsor class

Conditions

Branch Retinal Vein Occlusion

Interventions

DRUG: Ranibizumab
DRUG: Ranibizumab and laser

Sponsor

Fukushima Medical University